TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- TerrAscend Corp. (CSE:TER)
(“TerrAscend” or the “Company”), is pleased to announce that the Company has closed the first
tranche of its non-brokered private placement first announced on July 18, 2017. The Company has raised gross proceeds of $3,189,875
through the issuance of 3,037,976 Units for $1.05 per Unit, with each Unit consisting of one common share and one half of one
common share purchase warrant (each a “Unit”). Each whole warrant entitles the holder to purchase an additional
common share for a period of two years at an exercise price of $1.75. In connection with the closing of the first tranche of the
private placement, the Company has paid a finder's fee in the amount of $33,443.
TerrAscend intends to close a second tranche of its previously announced private placement in mid-August in
order to accommodate continuing investor interest. The Company may pay finders’ fees in the amount of 7% based on the sale of the
Units purchased by subscribers introduced to the Company by such finders.
The Company intends to use the proceeds from this private placement to build out additional space in its
existing facility, commence construction of its drug preparation premises, further develop its subsidiary Terra Health Network, and
for other working capital needs.
Securities issued pursuant to the private placement will be subject to a four-month hold period from the
distribution date and subject to all necessary regulatory approvals, including the approval of the Canadian Securities
Exchange.
About TerrAscend
TerrAscend is a vertically-integrated Canadian cannabis company that strives to create and deliver quality products and services
that meet the evolving needs of the cannabis market. The Company provides support to patients through its wholly-owned
subsidiaries, Solace Health Inc. (“Solace Health”), a licensed producer of medical cannabis under
the Access to Cannabis for Medical Purposes Regulations, Terra Health Network Inc. (“Terra Health”),
a clinical support program and education platform led by health care professionals, and Solace Rx Inc.
(“SolaceRx”), a drug preparation premises for non-cannabis formulations. Please visit www.TerrAscend.com for more information about the Company.
Forward-looking statements
This news release contains "forward-looking information" within the meaning of applicable securities laws. Although TerrAscend
believes in light of the experience of its officers and directors, current conditions and expected future developments and other
factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable,
undue reliance should not be placed on them because TerrAscend can give no assurance that they will prove to be correct. Readers
are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially
from those contemplated by these statements. The statements in this press release are made as of the date of this release.
TerrAscend undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of
TerrAscend, its securities, or financial or operating results (as applicable). TerrAscend disclaims any intent or obligation to
update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise,
other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or
accuracy of the content of this news release.
For more information: Ari Unterman Investor Relations 1-855-TERRA-95 x100 aunterman@terrascend.com
